Magnesium for Restless Legs Syndrome: Dosing, Form, and the Trial Record

Magnesium is one of the most consistently recommended over-the-counter options for restless legs syndrome (RLS, also called Willis-Ekbom disease), particularly in primary care and during pregnancy. The controlled-trial record is thinner than the recommendation footprint, but the biological rationale, modest signal, and safety profile make a trial reasonable for many patients before stepping up to dopamine agonists or alpha-2-delta ligands.

The neurology of RLS and where magnesium plausibly fits

RLS is driven by central iron deficiency in the substantia nigra and dorsal striatum and downstream dopaminergic dysfunction, even when systemic iron stores look normal. Standard guideline-recommended therapy is intravenous iron when ferritin is below 75 ng/mL with transferrin saturation under 45 percent, then alpha-2-delta ligands (gabapentin, pregabalin) or dopamine agonists [1]. Magnesium acts as an NMDA receptor antagonist, modulates voltage-gated calcium channels, and is required for normal dopamine receptor function — all relevant to the RLS pathway, though no specific magnesium deficiency has been identified in RLS pathophysiology.

The actual trial evidence

The most-cited trial is Hornyak and colleagues 1998, an open-label study of 10 patients with mild to moderate RLS or periodic limb movement disorder treated with oral magnesium 12.4 mmol (~300 mg elemental) at bedtime for 4-6 weeks. Subjective improvement and reduced periodic limb movements on polysomnography were reported [2]. Marshall and colleagues 2019 systematic review identified seven trials of magnesium for various sleep complaints including RLS and concluded the evidence base was weak but suggestive [3]. A separate 2023 randomized trial by Mohri and colleagues in iron-replete pregnant women with RLS showed magnesium 300 mg/day at night reduced symptom severity scores significantly compared with placebo [4]. The trial base remains small and heterogeneous.

Which magnesium form makes sense for RLS

Forms that produce minimal laxation at therapeutic doses are preferred for chronic nighttime use: magnesium glycinate, magnesium malate, magnesium taurate, and magnesium L-threonate. Magnesium oxide and citrate have lower elemental absorption percentages and more frequent loose stool side effects, though they are cheaper and effective for some users. Magnesium L-threonate is marketed for cognitive effects via better CNS penetration; whether that matters for RLS specifically has not been demonstrated. The pragmatic choice for many people is 200-400 mg elemental magnesium glycinate taken 30-60 minutes before bed.

When magnesium is unlikely to be enough

RLS with severe symptom intensity, frequent nightly awakenings, or augmentation history (where dopamine agonist therapy paradoxically worsens RLS over time) requires specialist evaluation. Patients with chronic kidney disease (CKD stage 4-5) should not take supplemental magnesium without nephrology guidance due to retention risk. Iron repletion comes first when ferritin is low — magnesium does not substitute for ferric carboxymaltose infusions in iron-deficient RLS [5]. Patients on quinolone antibiotics, bisphosphonates, or levothyroxine need to space magnesium dosing several hours apart due to chelation.

Putting it together for a primary-care trial

For mild-to-moderate RLS in someone with adequate iron status, a 4-8 week trial of magnesium glycinate 200-400 mg elemental at bedtime is low-risk and low-cost. Combining with sleep hygiene, screening for medications that worsen RLS (sedating antihistamines, SSRIs, antipsychotics, dopamine antagonists like metoclopramide), and addressing caffeine and alcohol intake produces more improvement than magnesium alone. Failure to improve, or augmentation on dopamine agonists, justifies referral to a sleep specialist or neurologist who can use the full guideline-directed pharmacotherapy menu.